Related Experiment Video
Updated: Jun 20, 2026
07:59
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2-Mutant Non-Small
Christine M Lovly1, Christina Baik2, Misako Nagasaka3
1Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA.
JCO Precision Oncology
|June 18, 2026
Summary
This study reveals that patients with HER2-mutant non-small cell lung cancer (NSCLC) with tyrosine kinase domain (TKD) mutations differ genetically from those with non-TKD mutations. Current treatments offer suboptimal outcomes, indicating a need for novel therapies for advanced NSCLC.
Area of Science:
- Oncology
- Genetics
- Clinical Research
Background:
- HER2 mutations are a rare but actionable subset of non-small cell lung cancer (NSCLC).
- Understanding the real-world characteristics and treatment patterns of HER2-mutant NSCLC is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the real-world characteristics, treatments, and overall survival (OS) of US patients with HER2-mutant advanced NSCLC.
- To compare these factors between patients with HER2 tyrosine kinase domain (TKD) and non-TKD mutations.
Main Methods:
- Observational study utilizing deidentified data from the Flatiron Health-Foundation Medicine NSCLC Clinico-Genomic Database.
- Inclusion criteria: advanced/metastatic NSCLC with oncogenic HER2 mutations.
- Assessment of mutation prevalence, coaberrations, treatment patterns, and OS.
Main Results:
- 3.8% of patients had HER2 mutations, with 1.8% being oncogenic (n=262).
- Patients with oncogenic TKD mutations (n=197) were younger, more often female, and never-smokers compared to non-TKD (n=65).
- Median OS after first-line treatment was 13.5 months; second-line was 11.1 months. First-line chemoimmunotherapy showed better OS (21.1 months) for TKD vs. non-TKD (11.7 months).
Conclusions:
- HER2-mutant NSCLC patients with TKD mutations exhibit distinct characteristics and genetic profiles compared to non-TKD mutation patients.
- Standard-of-care treatments for advanced HER2-mutant NSCLC yield suboptimal real-world outcomes.
- There is a significant unmet need for novel therapeutic strategies for this patient population.
